Scheiner Zachary 4
4 · LENZ Therapeutics, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
LENZ Director Zachary Scheiner Receives 22,100-Share Award
What Happened
Zachary Scheiner, an outside director of LENZ Therapeutics, was granted a derivative award (stock option) covering 22,100 shares on June 15, 2026. The grant is reported at $0.00 per share (no cash paid at grant). This is an award/acquisition (not a sale or exercise) and does not represent an immediate sale of shares.
Key Details
- Transaction date and filing date: 2026-06-15 (filed same day). Transaction code: A (award/grant).
- Award size: 22,100 shares; reported price: $0.00 (derivative).
- Vesting: 100% of the option vests on the earlier of June 15, 2027 or the date of the next annual meeting, conditioned on Scheiner continuing as an Outside Director (Footnote F1).
- Beneficial ownership: Scheiner holds the option for the benefit of RA Capital-managed vehicles (RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account) and disclaims beneficial ownership; any net cash/stock from exercise will offset advisory fees (Footnote F2).
- Shares owned after transaction: not reported as direct beneficial ownership is disclaimed in the filing.
- Filing timeliness: filed the same day (no late filing indicated).
Context
This filing documents a director equity award (an option-like derivative) rather than an option exercise or open-market trade. Because the award is held for RA Capital funds and beneficial ownership is disclaimed, the grant reflects compensation/arrangement terms rather than a personal purchase or sale by the director.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1][F2]2026-06-15+22,100→ 22,100 totalExercise: $6.63Exp: 2036-06-15→ Common Stock (22,100 underlying)
Footnotes (2)
- [F1]Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.